Organic Active Ingredients TRIZ Cases

6-aza tetracyclic oxazepines target KRasG12D to restore Ras signaling termination and suppress cancer cell proliferation and metastasis.

Embedding corallopyronin A in a water-soluble polymer creates a stable amorphous dispersion for oral dosing with improved solubility and bioavailability.

Targeting DGAT1 relieves opioid-induced constipation by increasing fecal output while avoiding the broad side effects of standard laxatives.

Multi-ethnic genomic screening links ALS risk genotypes to compounds that prolong motor neuron neurite length and speed candidate selection.

Formula 1 compounds selectively block prostaglandin transporter activity to raise PGE2 and prostacyclin with fewer off-target effects.

Controlled-release D-mannose granules use HPMC, oils, and waxes to sustain urinary levels, inhibit adhesion, and reduce frequent dosing.

An acidic selenate or seleno-amino acid formulation keeps parenteral selenium stable in storage and avoids manual bag mixing errors.

Combining ATR inhibitor AZD6738 with paclitaxel improves chemotherapy response in melanoma after prior PD-1 or PD-L1 immunotherapy.

Specific thienopyrimidine salts and crystal forms improve stability, flowability, and oral bioavailability for GnRH receptor antagonists.

Combining plerixafor stem cell mobilization with low-dose tacrolimus supports graft acceptance while reducing chronic immunosuppression side effects.

A five-step cyclization, chiral reduction, and hydrolysis route cuts synthesis steps while delivering high-purity pyrrolopyridine derivatives for mass production.

Pulsed GnRH delivery restores natural secretion rhythms to reverse olfactory and cognitive impairments linked to GnRH deficiency.

A two-phase PI3Kδ inhibitor regimen uses induction then lower-dose maintenance to preserve efficacy while reducing toxicity in B-cell disorders.

Structural tuning of pyrazolo[1,5-a]pyrimidine-7-amine derivatives improves CDK9 selectivity, potency, and in vivo pharmacokinetics.

A hydrophilic self-immolative linker improves ADC stability, solubility, pharmacokinetics, and anti-tumor activity in low-receptor tumors.

Genetically modified Pantoea agglomerans produces high-purity low-mass lipopolysaccharide directly, cutting gel filtration cost and easing scale-up.

Rapid IV cangrelor provides reversible platelet inhibition after pediatric shunt surgery or stent implantation to cover the early thrombosis risk window.

Targets immune cell surface antigens to deliver therapeutic agents in vivo, avoiding ex vivo cell modification and autologous collection.

Formula I aza-quinoline compounds inhibit EZH2 to reactivate gene expression, suppress tumor growth, and support broader cancer treatment.

Pyridazinone compounds block TRPC4/5 channels to address the lack of effective inhibitors for kidney and liver disease treatment.

Heterobifunctional compounds degrade TTBK1 instead of competing with ATP, lowering tau phosphorylation and total tau in tauopathies.

Controlled crystallization forms 3',3'-cGAMP hydrate crystals with lower hygroscopicity, better shelf life, and easier scale-up than lyophilized powder.

Gentle centrifugation, microfiltration, and freeze-drying preserve bovine milk exosome membranes and miRNA in a stable powder.

Defined 36-50 saccharide heparan sulphate fragments improve BMP2 binding to enhance osteoblast differentiation, bone repair, and wound healing.

Targeting Cryptosporidium PI4K, these compounds improve treatment effectiveness where current therapies fall short, especially in vulnerable patients.

Targeted FXII RNAi delivery to liver cells suppresses Factor XII expression to prevent thrombosis and angioedema with lower hemorrhage risk.

Small molecules targeting conserved hemagglutinin fusion regions block viral entry and help address influenza drug resistance.

A stable thiol-linked conjugate avoids amide hydrolysis and reverse Michael addition, improving tumor exposure while reducing toxicity.

Chemical modification of quinolone analogs enables oral tumor treatment with improved bioavailability, metabolic stability, and lower toxicity.

Novel pyridinyl-triazolyl benzothiazinone derivatives strengthen ASK-1 inhibition for treating metabolic and other ASK-1 mediated diseases.

BDDE crosslinking keeps triamcinolone evenly dispersed in hyaluronic acid gel, extending intra-articular release without surfactant instability.

Oral sodium benzoate inhibits D-amino acid oxidase to enhance NMDA receptor function and treat refractory anti-NMDAR encephalitis.

Direct prostate injection of a sustained-release cytostatic or cytotoxic formulation treats BPH with faster local effect and less urethral trauma.

Electrowetting and a porous diffusion layer enable on-demand transdermal release, variable dosing, and multi-drug delivery from one patch.

C-17 substitution in 19-alkoxy neuroactive steroids improves GABA A receptor activity, anesthetic efficacy, solubility, and contamination control.

Heteroaryl methacrylic acids improve metabolic stability and systemic exposure while reducing cytokine release through NRF2 activation.

A glucuronic acid-1-phosphate and tetracalcium phosphate graft balances rapid setting, bond strength, biocompatibility, and controlled resorption.

An EGFR-targeted ADC uses antibody-guided delivery and a cleavable linker to treat resistant solid tumors with lower toxicity.

Small molecules block UBE3A-mediated ubiquitination, offering a drug lead for autism-related overactivity and HPV-driven cancers.

Bridged nucleic acids placed around mismatch sites improve intracellular DNA editing by resisting mismatch repair and raising editing yield.

Temporary high-dose dexamethasone or betamethasone depletes lymphocytes while sparing other cells, reducing toxicity and relapse risk.

Targeting MAT2A with sulfone derivatives disrupts methionine salvage and suppresses growth in MTAP-deleted cancers.

Cyclodextrin-based leucovorin calcium formulations prevent crystallization in refrigerated storage, enabling a clear ready-to-use injection.

Controlled-OTR translucent polypropylene bags keep dilute phenylephrine stable without opaque overwraps, enabling impurity inspection and longer shelf life.

Pridopidine targets Sigma-1 and dopamine D2 receptors to reduce dystonic muscle contractions across multiple dystonia types.

By crossing the blood-brain barrier and raising PGC-1α in the brain, this composition protects dopaminergic neurons beyond symptom relief.

Novel Formula I small molecules inhibit RSV and MPV replication, offering a safer, more accessible alternative to vaccines and monoclonal prophylaxis.

Blocking CD47 signaling with 1,2,4-oxadiazole compounds boosts macrophage phagocytosis and helps restore antitumor immune surveillance.

A one-pot tedizolid intermediate route uses Vilsmeier chemistry to avoid cyanide, azide, palladium, and ultra-low-temperature processing.

Anti-V5 and fluorescent antibody readout enables hybrid cyclic libraries to screen the human proteome without tag interference.

New crystalline, salt, and co-crystal forms of a pyrimido-diazepine PLK1 inhibitor improve stability, handling, and bioavailability while limiting toxicity.

When direct RAS inhibitors fail, mutant peptide compositions and TCRs enable HLA-specific immune killing of G12-mutant cancer cells.

Timed kit compartments, non-verbal instructions, and app tracking improve MRSA decolonization compliance while limiting resistance.

Combining asparagine restriction with ASNS synthetic lethal partner inhibition blocks metabolic rewiring and suppresses melanoma and pancreatic tumors.

Topical Wnt inhibitors reduce hyperactive WNT signaling in TMEM79-linked atopic dermatitis to improve skin barrier integrity.

Cyclo-Z targets NF-κB-driven inflammation and immune dysfunction to restore β-cell activity and insulin sensitivity in diabetes.

Lumateperone mono-tosylate capsules improve CNS treatment by combining rapid onset with selective serotonin and dopamine pathway targeting.

Timed vaccination before or between cladribine cycles helps preserve autoimmune treatment efficacy while lowering infection risk.

Selective GYS1 inhibition lowers pathological tissue glycogen while preserving normal metabolism through isoform-targeted, partial enzyme suppression.

Antisense oligonucleotides suppress MAT1a expression to improve adiposity, insulin sensitivity, triglycerides, and fatty liver.

Specific HPBCD isomers isolated by nanofiltration improve selective cholesterol binding over gross mixtures for targeted therapeutic delivery.

A four-drug hair loss regimen combines DHT inhibition with minoxidil-driven blood flow to improve regrowth while limiting monotherapy side effects.

Bifunctional PROTACs link a VHL ligand to a target binder to recruit E3 ligases and drive selective protein ubiquitination and degradation.

Isoquinoline carboxamides inhibit aberrant Wnt signaling to address cancers, fibrotic disorders, and bone or cartilage diseases.

AAV8-delivered shRNA suppresses SOX4 to improve bile duct development and liver function in Alagille syndrome without transplantation.

Stopping CYP2C9 inhibitors before deuruxolitinib dosing helps limit excess JAK inhibitor exposure and related adverse events.

Biodegradable polymer microneedles combine a flexible backing with homogeneous drug distribution to enable self-application and 24-hour release.

An IV ganaxolone bolus plus continuous infusion maintains therapeutic plasma levels to suppress status epilepticus and prevent relapse.

Chemically modifying only one strand of circular dsDNA lowers immunogenicity while preserving transcription and therapeutic protein expression.

Stimulated immune-cell vesicles combine exosomes, apoptotic bodies, and migrasomes to suppress cancer cells without drug loading.

Optimized cabotegravir particle size and excipients keep high-concentration suspensions resuspendable, stable, and less reactive at injection sites.

A CD79b-targeted immunoconjugate combined with lenalidomide and anti-CD20 therapy extends response duration in relapsing follicular lymphoma.

Hepatic arterial infusion of trifluridine treats liver cancer while limiting liver enzyme rise and avoiding severe toxicity seen with floxuridine.

Selective JAK1/JAK2 inhibitors target JAK/STAT-driven skin inflammation in hidradenitis suppurativa and improve clinical response.

Liposomal brilaroxazine targets psoriatic lesions to reduce skin inflammation and cytokines while limiting systemic side effects.

Targeted CNV detection links schizophrenia-related loci to personalized piracetam therapy, improving efficacy while reducing residual symptoms.

pH-tuned lipid nanoparticles deliver RNA to hepatic stellate cells without ligands, improving stability and helping suppress liver fibrosis.

Specific formula (I) compounds improve STING activation and cytokine signaling to boost interferon-driven antiviral and antitumor immunity.

Small-molecule compounds block the menin-MLL interaction to improve leukemia treatment efficacy and address high relapse in MLL-translocation disease.

A two-phase dienogest and ethinyl estradiol release profile maintains contraceptive efficacy and bleeding control despite missed or delayed doses.

Deoxyguanosine and PNP inhibition restore nucleotide balance in GUK1-related MDDS, raising mtDNA levels and easing multisystem symptoms.

Targeting STAT3 with diarylacetylene compounds suppresses diverse tumor cells at low doses while avoiding the high toxicity of conventional chemotherapy.

Oral dexpramipexole lowers blood and lung eosinophils in moderate to severe eosinophilic asthma, improving lung function and control.

Small-molecule oxadiazole and thiadiazole compounds inhibit PD-1 signaling, offering a simpler oral alternative to biologic immunomodulators.

High-concentration 7-hydroxymitragynine inhalation raises delivered dose and speeds therapeutic onset without adding device complexity.

Rapidly disintegrating oral corticosteroid compositions improve upper GI mucosal contact while limiting systemic absorption and side-effects.

Blocking the PERK-eIF2α adaptive stress pathway exposes PTEN-loss, Myc-activated tumors to lethal proteotoxic stress.

An anti-ticagrelor antibody rapidly restores platelet function during surgery or invasive procedures to reduce bleeding risk.

Structural changes to quinone derivatives improve Leishmania killing while lowering host-cell toxicity and enabling topical or oral treatment.

Prodrug conversion and dosing strategies limit in vivo maribavir isomerization to maintain active drug levels and more consistent antiviral efficacy.

A GC-rich 3′ sequence enables enzymatic tailing of chemically modified mRNA with more uniform long polyA tails for stable expression.

Novel imidazopyridine compounds inhibit ERK5 to suppress tumor growth and address limited treatment response across cancers.

Targeted SMDC pretreatment removes immunosuppressive fibroblasts so CAR-expressing lymphocytes infiltrate tumors more effectively with lower off-target toxicity.

A dual polymer coating on an intracranial balloon catheter enables sustained local drug release in brain tissue while reducing systemic side effects.

A 6-month subcutaneous lenacapavir sodium salt formulation addresses daily PrEP dosing limits while providing long-term HIV-1 and HIV-2 protection.

Urea compounds are engineered to activate orexin receptors, addressing weak receptor modulation in neurological and psychiatric disorders.

Selective benzamide CTPS1 inhibitors curb immune and cancer cell proliferation while avoiding the toxicity seen with non-selective CTPS targeting.

Novel THP-substituted pyrimidinedione compounds stabilize cardiac myosin to improve diastolic function and reduce left ventricular obstruction in HCM.

Cyclohexyl salicylate activates olfactory receptor 2A4/7 to stimulate hair growth and thickening while avoiding the side effects of existing treatments.

Oral acotiamide dosing improves voiding pressure and urine flow while preserving bladder compliance and avoiding cholinergic crisis.

L-selectin-coated polymeric particles mimic lymphocyte homing to deliver immunoregulatory drugs to lymphoid tissues and limit systemic toxicity.

Novel isoindoline modulators recruit substrate proteins to CRBN for ubiquitin-proteasome degradation and broader therapeutic applications.

Chemical entities recruit E3 ligases to degrade NEK7, attenuating NLRP3 inflammasome activation and excessive inflammation.

High-aspect-ratio paclitaxel crystals project from porous substrates to improve coating robustness and make vascular drug delivery more consistent.

Blocking miR-4453 from binding HBV’s 5′ epsilon signal suppresses viral replication through a targeted nucleic acid composition.

Chronic inflammatory skin disorders face corticosteroid side effects and barrier damage; a plant-based composition targets inflammation, oxidative stress, and repair.

Selective sulphonyl urea compounds address limited NLRP3 specificity and potential side effects while supporting targeted inhibition across inflammatory disorders.

Small molecules cross the blood-brain barrier to activate oxytocin receptors, targeting social deficits and drug-seeking behavior.

Genetic screening identifies lysosomal variants, guiding pathway-modulating therapy to reduce Aβ and α-Syn aggregation.

Target KMT9 selectively to reduce cancer-cell proliferation and tumor growth while limiting off-target effects on other enzymes.

Modular dendron-like heads, linkers, and lipophilic tails support targeted delivery while protecting drugs and limiting cytotoxicity.

GalNAc-linked RNAi agents silence C3 in hepatocytes, enabling durable proximal complement inhibition with less frequent dosing.

Reversal immunoglobulins bind NPR1 agonist antibodies to counter hypotension and reflex tachycardia while stabilizing blood pressure.

Specific bacteria grown on mammalian milk oligosaccharides raise acetate and lactate in an infant gut while reducing pathogens and inflammation.

Varying heterocyclic rings, substituents, and linkers improves TNFα modulation for inflammatory and autoimmune disease treatment.

An ampule-in-tube applicator uses filtration and a tapered tip to deliver controlled droplets without contact or shard contamination.

A conjugated half-duplex compound combines complementary oligonucleotides to improve systemic delivery to CNS tissue across the blood-brain barrier.

Simian RhAd54–RhAd67 vectors address pre-existing anti-Ad5 immunity while preserving potent vaccine immunogenicity.

p62/SQSTM1 compositions modulate inflammatory cytokines and osteogenic factors to mitigate chronic inflammation and protect bone.

Rapid absorption can cause short half-life and fluctuating serum levels; this oral formulation releases minoxidil gradually over 12 hours.

Limited response to existing therapies motivates naphthoquine phosphate as an immunosuppressive option for autoimmune disease treatment.

Structurally novel heterocyclic compounds target TYK2 selectively while supporting brain penetration and lower toxicity in inflammatory disease treatment.

Thiol-containing compounds pair nitric oxide donation with ROS scavenging to address oxidative stress and support endothelial function.

Sequence-specific polynucleic acids use RNA interference to lower ANGPTL3 expression and plasma lipids without severe cytotoxic side effects.

Flow cytometry measures platelet-surface FcγRIIa to identify medication-independent thrombosis risk and guide antithrombotic therapy.

Combining Favipiravir with an IMPDH inhibitor blocks viral RNA replication and purine biosynthesis, increasing potency while reducing dosage needs.

Aptamer-linked therapeutic compounds target glioma cells, cross the blood-brain barrier, and limit exposure of normal tissues.

A porous powder aggregate combines biocompatible hemostatic material with a binder to absorb blood quickly and resist washout at difficult wound sites.

Structural optimization reduces hydrophobicity while preserving gp130 binding, improving solubility for transdermal treatment of inflammatory disorders.

Polymer coatings can cause thrombosis and incomplete release; fatty alcohol or aldehyde excipients bind rapamycin for controlled delivery from the stent surface.

Poorly soluble MK-9 is formulated as stabilized nanoparticles to improve gastrointestinal absorption and raise serum MK-9 levels.

High-viscosity eye formulations are delivered in two stages, using lubricious material first to limit air trapping and improve dose accuracy.

SMTP compounds promote plasminogen-mediated thrombolysis and anti-inflammatory action to reduce cerebral hematoma, edema, and brain pressure.

Tap and shake the gel before administration to restore aripiprazole homogeneity and reduce injection resistance to 30 N or less.

Pairing an anti-CAPRIN-1 antibody with an N-glycoside-linked sugar chain inhibitor strengthens antitumor effects in cancer treatment.

A daily 1–80 mg/kg regimen uses a heterocyclic phosphinic compound to inhibit GnT-V and reduce tumor proliferation.

CD206-targeted dextran conjugates deliver therapeutic payloads to M2-like TAMs, promoting M1 repolarization while reducing toxicity.

Defined MALT1 compound series address inadequate activity modulation across autoimmune, inflammatory, and cancer indications.

See how Formula I compounds tune molecular properties to preserve RIPK1 inhibition while crossing the blood-brain barrier.

Regnase-1 levels support pulmonary hypertension diagnosis and prognosis, while immune-cell deficiency creates a spontaneous PAH model.

Vitamin B6, B9, and B12 combine with transfer factor, L-arginine, and L-citrulline to enhance eNOS activity and regulate cellular immunity.

Dual angiotensin and endothelin receptor blockade targets persistent proteinuria in FSGS, IgA nephropathy, and membranous nephropathy.

Combining a CLDN18.2 antagonist with PD-1/PD-L1 inhibition aims to improve response in tumors with low or absent PD-L1.

Glycosyl modification improves camptothecin prodrug solubility and supports tumor targeting through sugar transporters and β-glucuronidase activation.

Maintaining tropoelastin in aged or injured tissue gives endogenous factors time to support elastic fiber formation.

This case replaces inconvenient intravenous delivery with oral GLP1R agonist regimens that balance efficacy and side effects.

Multi-strain bacterial consortia convert ellagic acid into urolithin profiles that mimic human metabotypes A and B in vitro and in vivo.

Poor solid form and impurity control are addressed by acid or base addition salts that improve carebastine stability and purification.

BED treatments can provide modest benefits with side effects; this case combines psilocybin, psychotherapy, and integration sessions to target BED, anxiety, and depression.

Polyethylene oxide slows rapid initial release from ruxolitinib tablets, supporting sustained drug levels and fewer dosing-related side effects.

Sporoderm-broken Ganoderma lucidum spore powder undergoes ozone oxidation followed by simulated moving-bed chromatography to isolate ergosterol peroxide.

Pyrimidine sulfamide derivatives achieve 10000-fold ET A selectivity to reduce hepatotoxicity and CYP3A induction compared to dual antagonists.

Hydroxylated elovanoid derivatives provide localized neuroprotection and restore disrupted organ functions through enzymatic conversion of omega-3 fatty acids.

Multi-step synthesis of PDE10 inhibitors uses specific catalysts and reagents to resolve yield limitations in large-scale manufacturing.

A Glypican-1 biomarker enables specific identification of esophageal cancer cells through targeted binding agents.

N-acyl triazolopyrazine compounds resolve poor safety and limited CNS penetrability of non-peptide NK-3 antagonists through structural parameter optimization.

Dissolving rofecoxib in isosorbide dimethyl ether and propylene carbonate creates a topical composition that delivers localized pain relief.

Eliminating protection steps during N-acylation and cyclization preserves stereochemistry and improves chemical yield for pharmaceutical intermediates.

A triiodothyronine pulmonary composition enhances alveolar fluid clearance through direct intratracheal instillation or aerosol delivery.

Controlling moisture content during mixing resolves texture and density issues while eliminating the need for excessive sweeteners in high protein foods.

Segmented DGAT1 inhibitors using piperidine structures lower triglycerides while preserving specificity.

Spiro-condensed pyrrolidine derivatives target Cezanne 1 to overcome limited efficacy of current DUB inhibitors.

An integrated oximetry and drug delivery system automates naloxone administration to reduce emergency response time.

Adjusting pH to 5.0-6.0 with glycols prevents oxidative degradation, enabling stable high-concentration liquid formulations.

Segmented units with acidic intermediaries protect hydrochlorothiazide from alkaline degradation while maintaining simultaneous drug release.

Small molecule compounds modulate Wnt signaling to regenerate hair cells while preserving supporting cell populations and native cochlear structure.

A pharmaceutical composition combines pyrrolidone-5-carboxylic acid with citrulline, arginine, or asparagine to enhance skin hydration.

Composite surfactants prevent particle aggregation and liver scavenging to enhance bioavailability of poorly soluble therapeutic agents.

Intra-articular resiniferatoxin injection targets nociceptive neurons to provide sustained osteoarthritis pain relief.

A multi-step synthesis of a novel taxane compound using protected gemcitabine and docetaxel intermediates achieves high tumor growth inhibition rates.

Substituted heterocycles target undruggable c-MYC by interfering with MYC/Max DNA binding, overcoming transcription factor inhibition challenges.

Antisense oligonucleotides replace viral vectors to modulate T cells via exon skipping, reducing hepatotoxicity.

5-HT1A receptor antagonist triggers membrane depolarization and calcium influx in pancreatic beta cells to stimulate insulin secretion.

Two-stage oxidation of thebaine produces 14-hydroxycodeinone sulfate for direct oxycodone synthesis.

A transdermal polymer matrix for amphetamine delivery excludes reactive functional groups to ensure chemical stability.

Sustained release bupropion and naltrexone combinations decrease binge eating frequency and weight gain in obese patients with emotional eating profiles.

Dual-action aminoester compounds inhibit PDE4 and block M3 receptors to improve airflow in COPD patients while reducing systemic side effects.

Modifying imidazo[1,2-b]pyridazine core parameters enables selective targeting of casein kinase 1 epsilon and delta.

Dynamic tapered dosing prevents withdrawal effects while enhancing tissue viability and behavioral recovery after CNS trauma.

Local quality substituents on phenethylamine cores optimize therapeutic index and reduce side effects for psychiatric conditions.

Halide and sulfonate salts of dinitrodibenzoiodolium enhance inhibitor potency and specificity against DUOX-2 overexpressing cancer cells.

Administering cetirizine with famotidine achieves 85% positive responders, outperforming single-agent therapies.

Segmenting stable nicotine salt from a pH adjusting agent enables rapid in situ conversion to base, resolving volatility and slow absorption trade-offs.

Novel isoxazolyl ether compounds act as positive allosteric modulators for the GABAA alpha5 receptor subunit.

In situ gelling compositions convert from liquid to gel at physiological temperature for localized anti-inflammatory delivery.

Replacing hazardous methyl isocyanate with N-methyl carbamoylimidazole eliminates toxic reagent risks while maintaining high reaction yields.

Crystalline (R)-oxybutynin D-malate salts improve drug stability and bioavailability.

A sublingual l-epinephrine tablet disintegrates under the tongue to release active drug for rapid transmucosal absorption into systemic circulation.

Topical TGF-β signal inhibitor eye drops reduce endoplasmic reticulum stress in corneal endothelial cells.

Direct pullulan fermentation fluid forms capsules, eliminating energy-intensive drying steps.